Literature DB >> 30948344

Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.

K Yamashita1, R Hatae2, A Hiwatashi3, O Togao3, K Kikuchi3, D Momosaka3, Y Yamashita4, D Kuga2, N Hata2, K Yoshimoto2, S O Suzuki5, T Iwaki5, K Iihara2, H Honda3.   

Abstract

PURPOSE: The purpose of this study was to identify magnetic resonance imaging (MRI) features that are associated with telomerase reverse transcriptase promoter mutation (TERTm) in glioblastoma.
MATERIALS AND METHODS: A total of 112 patients with glioblastoma who had MRI at 1.5- or 3.0-T were retrospectively included. There were 43 patients with glioblastoma with wild-type TERT (TERTw) (22 men, 21 women; mean age, 47±25 [SD] years; age range: 3-84 years) and 69 patients with glioblastoma with TERTm (34 men, 35 women; mean age 64±11 [SD] years; age range, 41--85 years). The feature vectors consist of 11 input units for two clinical parameters (age and gender) and nine MRI characteristics (tumor location, subventricular extension, cortical extension, multiplicity, enhancing volume, necrosis volume, the percentage of necrosis volume, minimum apparent diffusion coefficient [ADC] and normalized ADC). First, the diagnostic performance using univariate and multivariate logistic regression analyses was evaluated. Second, the cross-validation of the support vector machine (SVM) was performed by using leave-one-out method with 43 TERTw and 69 TERTm to evaluate the diagnostic performance. In addition, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy for the differentiation between TERTw and TERTm were compared between logistic regression analysis and SVM.
RESULTS: With multivariate analysis, the percentage of necrosis volume and age were significantly greater in TERTm glioblastoma than in TERTw glioblastoma. SVM allowed discriminating between TERTw glioblastoma and TERTm glioblastoma with sensitivity, specificity, PPV, NPV, and accuracy of 85.7% [60/70; 95% confidence interval (CI): 75.3-92.9%], 54.8% (23/42; 95% CI: 38.7-70.2%), 75.9% (60/79; 95% CI: 69.1-81.7%), 69.7% (23/33; 95% CI: 54.9-81.3%) and 74.1% (83/112; 95% CI: 65.0-81.9%), respectively.
CONCLUSION: The percentage of necrosis volume and age may surrogate for predicting TERT mutation status in glioblastoma.
Copyright © 2019 Société française de radiologie. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Glioblastoma; Isocitrate dehydrogenase; Magnetic resonance imaging (MRI); Support vector machine; Telomerase reverse transcriptase (TERT)

Mesh:

Substances:

Year:  2019        PMID: 30948344     DOI: 10.1016/j.diii.2019.02.010

Source DB:  PubMed          Journal:  Diagn Interv Imaging        ISSN: 2211-5684            Impact factor:   4.026


  5 in total

1.  TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma.

Authors:  Zensho Kikuchi; Ichiyo Shibahara; Tetsu Yamaki; Ema Yoshioka; Tomoko Shofuda; Rintaro Ohe; Ken-Ichiro Matsuda; Ryuta Saito; Masayuki Kanamori; Yonehiro Kanemura; Toshihiro Kumabe; Teiji Tominaga; Yukihiko Sonoda
Journal:  Neurooncol Adv       Date:  2020-09-01

2.  Identification of magnetic resonance imaging features for the prediction of molecular profiles of newly diagnosed glioblastoma.

Authors:  Sung Soo Ahn; Chansik An; Yae Won Park; Kyunghwa Han; Jong Hee Chang; Se Hoon Kim; Seung-Koo Lee; Soonmee Cha
Journal:  J Neurooncol       Date:  2021-06-30       Impact factor: 4.130

3.  Noninvasive Prediction of TERT Promoter Mutations in High-Grade Glioma by Radiomics Analysis Based on Multiparameter MRI.

Authors:  Hongan Tian; Hui Wu; Guangyao Wu; Guobin Xu
Journal:  Biomed Res Int       Date:  2020-05-15       Impact factor: 3.411

Review 4.  Imaging diagnosis and treatment selection for brain tumors in the era of molecular therapeutics.

Authors:  Saivenkat Vagvala; Jeffrey P Guenette; Camilo Jaimes; Raymond Y Huang
Journal:  Cancer Imaging       Date:  2022-04-18       Impact factor: 5.605

5.  A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.

Authors:  Nayuta Higa; Toshiaki Akahane; Seiya Yokoyama; Hajime Yonezawa; Hiroyuki Uchida; Tomoko Takajo; Mari Kirishima; Taiji Hamada; Kei Matsuo; Shingo Fujio; Tomoko Hanada; Hiroshi Hosoyama; Masanori Yonenaga; Akihisa Sakamoto; Tsubasa Hiraki; Akihide Tanimoto; Koji Yoshimoto
Journal:  Cancer Sci       Date:  2020-09-06       Impact factor: 6.716

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.